ATX trends: OMV, Do & Co, Lenzing, voestalpine …



[ad_1]

The Vienna Stock Exchange closed again at a loss on Thursday. The growing number of corona infections plagued Europe. However, in the last operations, the reductions in the national stock market were somewhat limited. The brightest sentiment on Wall Street provided support. The leading ATX index fell 0.40 percent to 2,166.41, after losing 0.87 percent the day before. The ATX Prime closed 0.42 percent lower at 1,109.09 points.

On the US stock exchanges, attention turned to a possible rapprochement between Republicans and Democrats in negotiations over a crown aid package. House spokeswoman Nancy Pelosi said a deal had almost been reached on the stimulus package.

There were brief reports on the national stock market at the company level. BAWAG, AMAG, OMV and Palfinger will only present trade figures in the next reporting season in the next business week.

Among heavyweights, OMV shares lost 1.72 percent as of the report date. At the lower end of the price list, Do & Co newspapers fell at a 3.7 percent discount. Palfinger’s papers were down 2.9 percent. By contrast, Lenzing’s stock ranked first in Vienna with a 3.5 percent lead.

voestalpine closed with a moderate loss of 0.12 percent. The steel and technology group has to write off around 200 million euros separately in the current financial year 2020/21 (at the end of March). That will affect the result. The company said it was primarily due to asset impairments at the pig iron mill in Texas.

(23.10.2020)


author of the photo

one.

Actions on the radar:Semperit, Compound, Marinomed Biotechnology, Mold, SBO, Warimpex, Andritz, VIG, UBM, In fact, CA, Rather S, Strabag, OMV, Wienerberger, Zumtobel, Rosgix, Immofinanz, Kapsch TrafficCom, Rosenbauer, Palfinger, DO&CO, Hutter & Schrantz steel construction, Lenzing, Environmental technology SW, Viennese private bank, FACC, Merck KGaA, SAP, Deutsche Telekom, Daimler, RWE.


Random partner


Evotec
Evotec is a drug discovery and development company that drives approaches to the development of new pharmaceuticals through research alliances and development partnerships with pharmaceutical and biotech companies, academic institutions, patient organizations, and venture capital firms.

>> Visit 57 other partners at boerse-social.com/partner


Latest blogs

»How to build wealth and increase your satisfaction (Tim Schäfer)

»Infineon Technologies (IFX); The chipmaker is on the move; Behind …

»Helmut Fallmann rings the opening bell for Friday #chooseoptimism

»ATX trends: OMV, Do & Co, Lenzing, voestalpine …

»BSN Spitout AUT: Telekom Austria shoots series less days

»Exchange Social Depot Business Comment (Deposit Comment)

»With this climate you only had to go running (Christian Drastil via …

»History of the stock market 10/22: Palfinger with time surprise, Uniqa makes a …

»Verbund wow, Vienna is still red, Blümel should comply (Christian Drastil)

»Interesting jobs in listed companies: Uniqa, Verbund, A1 Telekom Austria (Leya …

[ad_2]